{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:24:48Z","timestamp":1777901088630,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T00:00:00Z","timestamp":1249430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T00:00:00Z","timestamp":1249430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Appl Imm"],"abstract":"<jats:p>Newborn mongrel dogs were sensitized with conjugates of ovalbumin (OA) and 2,4-dinitrophenol (OA-DNP&lt;sub&gt;3&lt;\/sub&gt;) in the presence of Al(OH)&lt;sub&gt;3&lt;\/sub&gt; to produce high levels of anti-OA and anti-DNP IgE antibody. At 4\u20136 months of age, when anti-DNP and anti-OA antibody levels reached titers of 64 by passive cutaneous anaphylaxis, the dogs underwent separate inhalation and intravenous challenges with conjugates of DNP and bovine gamma globulin (DNP&lt;sub&gt;15&lt;\/sub&gt;-BGG) and OA. Inhalation challenge with DNP&lt;sub&gt;15&lt;\/sub&gt;-BGG and OA resulted in 5- and 10-fold increases in airflow resistance, respectively. Intravenous challenge with either DNP&lt;sub&gt;15&lt;\/sub&gt;-BGG or OA produced profound anaphylaxis with 60\u201380% decreases in blood pressure, cardiac output and regional blood flows in the carotid, superior mesenteric and renal arteries, and the distal aorta. Treatment of sensitized dogs with 5 doses of 20 mg of conjugates of DNP and polyvinyl alcohol (DNP&lt;sub&gt;2&lt;\/sub&gt;-PVA) on alternate days resulted in (1) suppression of anti-DNP IgE antibody production; (2) abrogation of established airway and vascular anaphylactic sensitivities; (3) no change in regional blood flows, and (4) no effect on sensitivities to challenge with OA.<\/jats:p>","DOI":"10.1159\/000234256","type":"journal-article","created":{"date-parts":[[2009,8,12]],"date-time":"2009-08-12T09:53:17Z","timestamp":1250070797000},"page":"468-470","source":"Crossref","is-referenced-by-count":1,"title":["A Canine Model for the Study of Hapten-Specific Suppression of IgE-Mediated Bronchoconstriction and Anaphylaxis"],"prefix":"10.1159","author":[{"given":"W.","family":"Kepron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Sehon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,8,5]]},"container-title":["International Archives of Allergy and Applied Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/234256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000234256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:51:05Z","timestamp":1777632665000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000234256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000234256","archive":["Portico"],"relation":{},"ISSN":["0020-5915","2571-6662"],"issn-type":[{"value":"0020-5915","type":"print"},{"value":"2571-6662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,5]]}}}